BRPI0510719A - derivados de naftalimida, composição farmacêutica, uso e método de preparação dos mesmos - Google Patents

derivados de naftalimida, composição farmacêutica, uso e método de preparação dos mesmos

Info

Publication number
BRPI0510719A
BRPI0510719A BRPI0510719-9A BRPI0510719A BRPI0510719A BR PI0510719 A BRPI0510719 A BR PI0510719A BR PI0510719 A BRPI0510719 A BR PI0510719A BR PI0510719 A BRPI0510719 A BR PI0510719A
Authority
BR
Brazil
Prior art keywords
preparation
pharmaceutical composition
derivatives
naphthalimide derivatives
naphthalimide
Prior art date
Application number
BRPI0510719-9A
Other languages
English (en)
Inventor
Eric Van Quaquebeke
Gentiane Simon
Laurent Van Den Hove
Robert Kiss
Francis Darro
Original Assignee
Unibioscreen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unibioscreen Sa filed Critical Unibioscreen Sa
Publication of BRPI0510719A publication Critical patent/BRPI0510719A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DERIVADOS DE NAFTALIMIDA, COMPOSIçãO FARMACêUTICA, USO E MéTODO DE PREPARAçãO DOS MESMOS. A presente invenção refere-se a derivados de naftalimida substituída, sais farmaceuticamente aceitáveis dos mesmos e solvatos dos mesmos, que são utilizáveis para fabricar composições farmacêuticas para o tratamento de doenças proliferativas de células como câncer. A invenção também provê métodos para fabricar estes derivados.
BRPI0510719-9A 2004-05-05 2005-05-04 derivados de naftalimida, composição farmacêutica, uso e método de preparação dos mesmos BRPI0510719A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56846904P 2004-05-05 2004-05-05
EP04447114 2004-05-05
PCT/BE2005/000069 WO2005105753A2 (en) 2004-05-05 2005-05-04 Naphthalimide derivatives, methods for their production and pharmaceutical compositions therefrom

Publications (1)

Publication Number Publication Date
BRPI0510719A true BRPI0510719A (pt) 2007-11-20

Family

ID=34970401

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510719-9A BRPI0510719A (pt) 2004-05-05 2005-05-04 derivados de naftalimida, composição farmacêutica, uso e método de preparação dos mesmos

Country Status (8)

Country Link
US (1) US20070117836A1 (pt)
EP (1) EP1742920A2 (pt)
JP (1) JP2007536283A (pt)
AU (1) AU2005238096A1 (pt)
BR (1) BRPI0510719A (pt)
CA (1) CA2555718A1 (pt)
MX (1) MXPA06012660A (pt)
WO (1) WO2005105753A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
JP2009536169A (ja) * 2006-05-05 2009-10-08 ユニバイオスクリーン エス．アー． ５−尿素置換ナフタルイミド誘導体、製造方法、および癌治療用医薬組成物
EP2073806B1 (en) 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
HRP20150882T1 (hr) 2008-10-17 2015-09-25 Xenon Pharmaceuticals Inc. Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
PE20170202A1 (es) 2009-10-14 2017-03-24 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
RU2596488C2 (ru) 2010-02-26 2016-09-10 Ксенон Фармасьютикалз Инк. Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов
KR20150002794A (ko) 2012-04-12 2015-01-07 제논 파마슈티칼스 인크. 치료제로서 유용한 스파이로-옥시인돌 화합물을 위한 비대칭적 합성
JP6120311B2 (ja) * 2013-02-12 2017-04-26 学校法人銀杏学園 ポリフェノール化合物
CN103113300A (zh) * 2013-03-06 2013-05-22 广西中医药大学 一种具有抗肿瘤活性的化合物的制备方法和用途
CN106459097A (zh) 2014-07-01 2017-02-22 第三共株式会社 作为抗菌剂的三环苯并氧杂硼杂环戊烯类
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
WO2017218920A1 (en) 2016-06-16 2017-12-21 Teva Pharmaceuticals International Gmbh Asymmetric synthesis of funapide
CN112940059B (zh) * 2021-02-06 2022-05-27 河南大学 一种糖基修饰的萘酰亚胺-多胺缀合物、其制备方法及应用
CN116410233B (zh) * 2023-02-27 2024-08-09 河南大学 一种靶向TNBC的Pt（IV）-萘酰亚胺多胺配合物、其制备方法及应用
CN119119131B (zh) * 2024-09-11 2026-03-20 河南大学 一种基于Lamp2介导的能够逆转胶质瘤进展的萘酰亚胺-铂（IV）配合物及其应用
CN121895230A (zh) * 2026-02-09 2026-04-21 广西民族师范学院 一种萘酰亚胺衍生物-铂(ii)配合物、制备方法及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES459497A1 (es) * 1977-06-04 1978-04-16 Made Labor Sa Un metodo para la preparacion industrial de naftalimidas y sus derivados.
US5183821A (en) * 1983-09-19 1993-02-02 Laboratories Knoll, S.A. Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors
DE3614414A1 (de) * 1986-04-29 1987-11-05 Knoll Ag Neue benzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
DE4232739A1 (de) * 1992-09-30 1994-03-31 Knoll Ag Neue asymmetrisch substituierte bis-Naphthalimide
IL110460A (en) * 1993-08-18 2001-01-11 Basf Ag Bis-naphthalimides, their preparation and pharmaceutical compositions containing them
US6552544B2 (en) * 2001-04-05 2003-04-22 Varian, Inc. Detunable coil assembly and method of detuning RF coil for MRI
US6693198B2 (en) * 2002-04-22 2004-02-17 Xanthus Life Sciences, Inc. Amonafide salts
US20050192312A1 (en) * 2004-01-30 2005-09-01 Brown Dennis M. Naphthalimide dosing by N-acetyl transferase genotyping

Also Published As

Publication number Publication date
WO2005105753A2 (en) 2005-11-10
US20070117836A1 (en) 2007-05-24
CA2555718A1 (en) 2005-11-10
MXPA06012660A (es) 2007-03-23
EP1742920A2 (en) 2007-01-17
WO2005105753A3 (en) 2006-02-02
JP2007536283A (ja) 2007-12-13
AU2005238096A1 (en) 2005-11-10
WO2005105753A8 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
NI201000004A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
LTC1934174I2 (lt) Azetinidai kaip MEK inhibitoriai, skirti proliferacinių ligų gydymui
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
CR11199A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
BR112012008849A2 (pt) composto, composição farmacêutica, e, uso de um composto
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
UY32203A (es) Amino pirimidinas y su uso en terapia
BRPI0915084B8 (pt) composto, e, composição farmacêutica
UY29199A1 (es) Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones
BR122013028005B8 (pt) compostos de ciclopentanos de pirimidila hidroxilados e metoxilados, composição farmacêutica, kit e forma de dosagem oral compreendendo os referidos compostos, uso das referidas composições, bem como processo de preparação dos referidos compostos
BRPI0714803B8 (pt) compostos peptidomiméticos de smac, seus usos, e composição farmacêutica
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CR11857A (es) Compuestos pirazolicos 436
BRPI0919447B8 (pt) compostos derivados de ácido 1-amino-2- ciclobutiletilborônico, composição farmacêutica e uso dos mesmos para tratar câncer
CL2009001274A1 (es) Compuestos derivados de triazina sustituida, mediados por la inhibicion de la kinasa p13 y mtor; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de diferentes tipos de cancer.
UY30195A1 (es) Derivados de fenetanolamina, procedimiento de preparacion, composiciones que los contienen y aplicaciones
EA201000436A1 (ru) Стероидные [3,2-с]пиразольные соединения, обладающие глюкокортикоидной активностью
UY28271A1 (es) Compuestos químicos
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém
BR122018009866B8 (pt) métodos para preparar compostos de éter aminocicloexílico e compostos intermediários

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.